Trial Profile
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 29 Dec 2022
Price :
$35
*
At a glance
- Drugs Atacicept (Primary)
- Indications Systemic lupus erythematosus
- Focus Registrational; Therapeutic Use
- Acronyms APRIL-Sle
- Sponsors EMD Serono; Merck Serono
- 14 Nov 2022 Results (n=223) presented at the ACR Convergence 2022
- 04 Jun 2022 Primary results (n=283) assessing estimated glomerular filtration rate and proteinuria at week 52 from phase II portion of this trial presented at the 23rd Annual Congress of the European League Against Rheumatism
- 20 May 2022 According to a Vera Therapeutics media release, first-time results from a post-hoc analysis of this study presented at European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress, 2022